MARKET

ATRC

ATRC

AtriCure
NASDAQ

Real-time Quotes | Nasdaq Last Sale

37.96
-0.32
-0.84%
After Hours: 37.96 0 0.00% 16:15 10/23 EDT
OPEN
38.65
PREV CLOSE
38.28
HIGH
39.45
LOW
37.50
VOLUME
138.25K
TURNOVER
--
52 WEEK HIGH
51.76
52 WEEK LOW
23.17
MARKET CAP
1.71B
P/E (TTM)
-29.4058
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
AtriCure to Announce Third Quarter 2020 Financial Results
AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that it will release its third quarter 2020 financial results on Thursday, November 5, 2020.
Business Wire · 10/13 13:00
Do Hedge Funds Love AtriCure Inc. (ATRC)?
We know that hedge funds generate strong, risk-adjusted returns over the long run, which is why imitating the picks that they are collectively bullish on can be a profitable strategy for retail investors. With billions of dollars in assets, professional investors have to conduct complex analyses, spend
Insider Monkey · 10/06 21:41
AtriCure down 9% on Kerrisdale short call
Thinly traded AtriCure ([[ATRC]] -9.4%) is under modest pressure out of the gate this morning on the heels of a bearish report from Kerrisdale Capital Management who believes its growth
Seekingalpha · 09/30 13:54
AtriCure gets hit by Kerrisdale call
Thinly traded AtriCure ([[ATRC]] -9.4%) is under modest pressure out of the gate this morning on the heels of a bearish report from Kerrisdale Capital ManPlease see agement who believes
Seekingalpha · 09/30 13:54
Kerrisdale Capital is short Atricure, citing 'doomed to fail' Convergent procedure
Among other criticisms, Kerrisdale Capital cites valuation as part of its short thesis on Atricure (ATRC), given it's near the "highest valuation in its history."Investors' assumptions on a "widespread adoption"
Seekingalpha · 09/30 13:37
AtriCure, Inc.: Surgical Device Maker's Growth Engines Face Fatal Complications
AtriCure's Convergent procedure, on which its hopes for growth are pinned, is unlikely to gain traction given a poor safety profile and lack of incremental efficacy relative to catheter-based procedures.The TAM for AtriCure's core surgical ablation products is much smaller than AtriCure claims, and is almost completely saturated, leaving little room for the company's core business to grow.Real-time mapping and pulsed-field ablation are set to revolutionize catheter ablation to the detriment of both the Convergent procedure and Atricure's core surgical devices business.
Seekingalpha · 09/30 13:30
What We Learned About AtriCure's (NASDAQ:ATRC) CEO Compensation
This article will reflect on the compensation paid to Mike Carrel who has served as CEO of AtriCure, Inc...
Simply Wall St. · 09/28 11:39
AtriCure: Steady Growth, Lackluster Margins
AtriCure has been a steady revenue growth play in medtech.Troublesome is that the business has been losing money since the IPO fifteen years ago, although the burn rate is manageable and is ''financed'' with dilution.I appreciate growth, duration of growth, and prospects for further growth, and while losses do not create an immediate worry, lack of profitable growth limits my enthusiasm.
Seekingalpha · 09/18 00:48
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of ATRC. Analyze the recent business situations of AtriCure through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 8 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average ATRC stock price target is 55.63 with a high estimate of 63.00 and a low estimate of 50.00.
EPS
Institutional Holdings
Institutions: 247
Institutional Holdings: 45.91M
% Owned: 102.17%
Shares Outstanding: 44.93M
TypeInstitutionsShares
Increased
70
5.74M
New
63
3.66M
Decreased
50
4.69M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Medical Equipment, Supplies & Distribution
+0.07%
Healthcare Equipment & Supplies
+0.12%
Key Executives
Chairman/Independent Director
Scott Drake
President/Chief Executive Officer/Director
Michael Carrel
Chief Financial Officer/Senior Vice President
M. Andrew Wade
Chief Financial Officer
Angela Wirick
Chief Operating Officer
Douglas Seith
Senior Vice President/Director of Marketing
Justin Noznesky
Chief Technology Officer
Salvatore Privitera
Independent Director
Mark Collar
Independent Director
Daniel Florin
Independent Director
Regina Groves
Independent Director
B. Kristine Johnson
Independent Director
Mark Lanning
Independent Director
Karen Prange
Independent Director
Sven Wehrwein
Independent Director
Robert White
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About ATRC
AtriCure, Inc. is an atrial fibrillation (Afib) solutions company. The Company develops, manufactures, and sells devices designed primarily for the surgical ablation of cardiac tissue and systems designed for the exclusion of the left atrial appendage. It has various product lines for the ablation of cardiac tissue, including its Isolator Synergy Ablation System, for the treatment of persistent and longstanding persistent forms of Afib in patients undergoing certain open concomitant procedures. It has two primary product lines for cardiac tissue ablation, which include Radio Frequency Ablation Devices and cryoICE Cryoablation System, and a product line for left atrial appendage exclusion. The Company also sells Lumitip dissectors and the Estech line of reusable cardiac surgery (valve) instruments. Its cryoICE cryosurgery product line offers various cryoablation devices. Its AtriClip Left Atrial Appendage Exclusion System is designed to occlude the heart's left atrial appendage (LAA).
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of AtriCure Inc. stock information, including NASDAQ:ATRC real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ATRC stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ATRC stock methods without spending real money on the virtual paper trading platform.